Loading...
•
Sep 30, 2022
Wave Life Sciences Q3 2022 Earnings Report
Wave Life Sciences reported financial results for the third quarter ended September 30, 2022 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $39.0 million with revenue of $0.3 million in the third quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $122.0 million as of September 30, 2022.
Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CSF
Multidosing underway in Phase 1b/2a trial of WVE-N531 in boys with DMD amenable to exon 53 skipping; muscle biopsy data from initial cohort on track for 4Q 2022
Selected WVE-006 (Wave’s first RNA editing candidate) as development candidate for AATD with CTA submissions expected in 2023
Preclinical data presentations at OTS and ESGCT meetings highlighted potential of PRISM platform to develop potent and durable siRNA compounds and unlock new biology with AIMers
Forward Guidance
Wave expects that its existing cash, cash equivalents and short-term investments will enable the company to fund its operating and capital expenditure requirements to the end of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...